 |
Top 74 Startups that help to cure COVID-19
Oct 12, 2024 | By Jason Kwon | 15 |
These startups develop new diagnostic and treatment technologies for COVID-19, such as such as monoclonal antibodies, antiviral therapeutics and immune modulators.
1
Country: China | Funding: $288.8M
Tianjin CanSino Biotech is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.
Tianjin CanSino Biotech is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.
2
Country: USA | Funding: $3.9B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
3
Country: Germany | Funding: $2.1B
CureVac is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA.
CureVac is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA.
4
Country: Germany | Funding: $1.9B
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
5
Country: UK | Funding: $1.2B
babylon was founded with a single purpose: To put an accessible and affordable health service in the hands of every person on earth. How? We’ll do this by combining the ever growing computing power of machines, with the best medical expertise of humans to create a comprehensive, immediate and personalized health service and making it universally available.
babylon was founded with a single purpose: To put an accessible and affordable health service in the hands of every person on earth. How? We’ll do this by combining the ever growing computing power of machines, with the best medical expertise of humans to create a comprehensive, immediate and personalized health service and making it universally available.
6
Country: USA | Funding: $1.1B
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
7
Country: USA | Funding: $999.6M
Cue Health develops and manufactures medical diagnostic products which are used in clinical and at-home settings.
Cue Health develops and manufactures medical diagnostic products which are used in clinical and at-home settings.
8
Country: USA | Funding: $908.6M
Vir Biotechnology brings together cutting-edge innovations with scientific expertise and management.
Vir Biotechnology brings together cutting-edge innovations with scientific expertise and management.
9
Country: Canada | Funding: $887M
AbCellera Biologics offers development of antibody therapeutics to improve patient outcomes.
AbCellera Biologics offers development of antibody therapeutics to improve patient outcomes.
10
Country: USA | Funding: $622.5M
Carbon Health is a developer of a mobile-based healthcare network used to offer simple, convenient, and accessible healthcare.
Carbon Health is a developer of a mobile-based healthcare network used to offer simple, convenient, and accessible healthcare.
